Compare HRMY & NGVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRMY | NGVT |
|---|---|---|
| Founded | 2017 | 1964 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.4B |
| IPO Year | 2020 | 2015 |
| Metric | HRMY | NGVT |
|---|---|---|
| Price | $42.11 | $70.56 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 2 |
| Target Price | $44.11 | ★ $72.50 |
| AVG Volume (30 Days) | ★ 603.1K | 190.8K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.97 | ★ 61.10 |
| EPS | 1.84 | ★ 2.67 |
| Revenue | $868,453,000.00 | ★ $1,167,600,000.00 |
| Revenue This Year | $19.75 | $3.63 |
| Revenue Next Year | $12.88 | $0.50 |
| P/E Ratio | ★ $23.20 | $25.99 |
| Revenue Growth | ★ 21.51 | N/A |
| 52 Week Low | $25.52 | $45.85 |
| 52 Week High | $43.49 | $79.29 |
| Indicator | HRMY | NGVT |
|---|---|---|
| Relative Strength Index (RSI) | 69.47 | 40.40 |
| Support Level | $34.87 | $68.66 |
| Resistance Level | N/A | $69.97 |
| Average True Range (ATR) | 1.24 | 1.94 |
| MACD | 0.29 | -0.31 |
| Stochastic Oscillator | 86.77 | 23.28 |
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Ingevity Corp is a chemical manufacturer based in the United States. It conducts its operations through three segments, namely Performance Chemicals, Advanced Polymer Technologies, and Performance Materials. The bulk of its revenue is generated by the Performance Chemicals segment which deals with the manufacture and sale of specialty chemicals that find their use in a range of processes such as asphalt paving, oil exploration and production, agrochemicals, adhesives, lubricants, and publication inks. The Performance Materials segment, on the other hand, focuses on automotive carbon products used in automobiles. The Advanced Polymer Technologies segment produces caprolactone and caprolactone-based specialty polymers. The company generates the majority of its revenue from North America.